30 US companies filed quarterly results with the SEC (8-K Item 2.02). We read 24 and called the likely one-week price move. Calls are graded in the open.
XTI Aerospace reported a revenue increase of 46.1% year-over-year and a significant reduction in G&A expenses, with adjusted EBITDA of $1.6 million, and reiterated its outlook for 2026, including full year revenue of $125-130 million, but the filing lacks a significant quantified surprise to move the stock beyond 1.5% in a week
OUR ANALYSIS → VIEW 8-K →Lifeward Ltd. reported an 18% year-over-year increase in AlterG revenue and is transitioning ReWalk to a capital-efficient channel-partner distribution model, but overall revenue decreased 12% due to lower ReWalk sales and adverse foreign exchange rate fluctuations.
OUR ANALYSIS → VIEW 8-K →The company announced a PIPE financing of up to $22.3 million, which may lead to dilution, and reported a net loss of $7.6 million for the third quarter, with cash and cash equivalents of $15.2 million as of September 30, 2026. The financing and related option agreement with NantWorks may have implications for the company's future development and licensing plans.
OUR ANALYSIS → VIEW 8-K →PowerCompute reported a net income of $0.4 million, or $0.20 per share, with a 36% increase in Bitcoin production and a significant reduction in secured debt, which are positive quantified surprises
OUR ANALYSIS → VIEW 8-K →The company's 1-for-7 reverse stock split is intended to increase the per share trading price and maintain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, but it will reduce the number of outstanding shares and may not necessarily lead to a sustained price increase. The termination of the merger agreement with Special Project Delivery, Inc. due
OUR ANALYSIS → VIEW 8-K →The company reported a net loss of $30.5 million and a cash balance of $116.2 million, with significant non-cash stock-based compensation expenses, and announced a non-binding term sheet with the U.S. Army for a heavy rare earth processing facility, but no quantified surprises or significant earnings beats were disclosed.
OUR ANALYSIS → VIEW 8-K →Binah Capital Group reported a 44.4% increase in GAAP net income to $2.6 million and a 74.1% increase in EBITDA to $4.7 million for the third quarter of 2026, driven by a 9.4% increase in total revenue to $50.6 million and a 5.0% increase in assets under management to $31.4 billion.
OUR ANALYSIS → VIEW 8-K →BIO-key International reported a 39% increase in Q3 software license fees and a significant improvement in gross margin to 90%, driven by growth in high-margin software licenses, with the company anticipating a solid finish to 2026 and a strong start to 2027
OUR ANALYSIS → VIEW 8-K →Quantum Cyber N.V. reported its first revenue of ~$1.0 million and announced an $8.0 million funding commitment from its CEO, but the funding commitment may be seen as a sign of potential cash flow issues or dilution, and the revenue, although a positive milestone, may not be enough to significantly impact the stock price in the short term.
OUR ANALYSIS → VIEW 8-K →The FDA lifted the clinical hold on ARD-101, and the company has a meeting scheduled with the FDA to discuss its proposed clinical development plan, which is a positive step towards resuming clinical development, but the stock's movement will depend on how investors react to the exploratory data from the terminated HERO and OLE trials, which showed numerically greater HQ-CT score reductions with A
OUR ANALYSIS → VIEW 8-K →Cineverse Corp. reported a 110% increase in revenue to $26.0 million and a net income of $3.2 million, or $0.11 per diluted share, with adjusted EBITDA of $1.7 million, beating prior year quarter results. The company also reaffirmed its fiscal year 2027 guidance of $115 to $120 million of revenue and $10 to $20 million of adjusted EBITDA.
OUR ANALYSIS → VIEW 8-K →Biofrontera Inc. reported strong third-quarter 2026 financial results, with 30% year-over-year revenue growth driven by a 29.8% increase in net product revenue to $9.1 million, and the company also received FDA approval for Ameluz for the treatment of superficial basal cell carcinoma, a significant catalyst for future growth. The revenue growth and new FDA approval are notable positives, but the c
OUR ANALYSIS → VIEW 8-K →Owlet's Q3 revenue and earnings are in line with expectations, but the company is withdrawing its 2026 financial outlook due to anticipated remediation expenses and demand uncertainty from a camera cable guard safety update, which may impact the stock price
OUR ANALYSIS → VIEW 8-K →PAVmed Inc. reported preliminary third quarter 2026 financial results, with Lucid Diagnostics' EsoGuard now fully reimbursed by Medicare nationwide, and provided a business update on its subsidiaries, including progress on Veris Health's implantable physiological monitor and FDA engagement for PortIO and Octeris, but no quantified surprises were disclosed beyond the Medicare reimbursement for EsoG
OUR ANALYSIS → VIEW 8-K →Fortress Biotech reported a 9% increase in total net revenue to $19.2 million for the third quarter of 2026 and repaid its credit facility in full, also announcing a license agreement for FB-607, a novel therapy for irritable bowel syndrome with diarrhea
OUR ANALYSIS → VIEW 8-K →Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, and presented positive interim clinical results from the ongoing BB-301 Phase 1b/2a study, but the update lacks a quantified surprise to drive a significant price move
OUR ANALYSIS → VIEW 8-K →The company is on track to report top-line data from its Phase 3 ENSURE trials in relapsing multiple sclerosis in December 2026, and is preparing for a potential New Drug Application submission, but there are no quantified surprises in the announcement.
OUR ANALYSIS → VIEW 8-K →The company reported progress in its programs, including a first look at data from its open-label study of IFx-2.0 with Keytruda, and received FDA clearance to begin a Phase 1b study of TBS-2025, but no quantified surprises were disclosed, and the company has access to a $50mm credit facility from its largest shareholder, which is a non-dilutive financing option.
OUR ANALYSIS → VIEW 8-K →Noodles & Company reported a 9.5% increase in comparable restaurant sales and a 34.3% increase in adjusted EBITDA, with net loss narrowing to $2.1 million, prompting a tightening of fiscal year 2026 guidance ranges. The company's improved sales momentum and margin expansion are notable positives, but debt remains significant at $101.0 million.
OUR ANALYSIS → VIEW 8-K →Digi Power X reports strong Q3 results with revenue up 85% and AI revenue up over 400% compared to Q2, with a significant contract value of approximately $402 million, but the company also announces plans to close a proposed $200 million credit facility, which may lead to increased debt and potential dilution. The company's AI revenue growth and large contract value are notable positives, but the
OUR ANALYSIS → VIEW 8-K →Milestone Pharmaceuticals announced cost-efficiency measures to extend cash runway through AFib-RVR Phase 3 data, including a 30% reduction in operating expenses, and reported $1.0 million in net product revenue for Q3 2026, up 73% from Q2 2026. The company's cash and equivalents of $145.4 million are expected to provide operating runway into late 2028.
OUR ANALYSIS → VIEW 8-K →Jade Biosciences reported a net loss of $35.1 million for the third quarter, with cash and investments of $476 million expected to provide a runway into the fourth quarter of 2028, and multiple clinical catalysts expected in 2027, including the initiation of a Phase 3 trial for JADE101 and interim data for JADE101 and JADE201, but no significant quantified surprises were disclosed
OUR ANALYSIS → VIEW 8-K →The company's third-quarter results show increased research and development expenses and a net loss of $6.1 million, with cash and cash equivalents of $22.3 million expected to fund operations into the third quarter of 2027. Advancement of TTI-109 into ulcerative colitis and other indications is subject to additional funding and IND clearance.
OUR ANALYSIS → VIEW 8-K →SBC Medical Group Holdings reported strong Q3 2026 results with 35% revenue growth, 66% increase in adjusted EBITDA, and 22% rise in net income attributable to SBC Medical, driven by higher management services revenue and clinic network expansion.
OUR ANALYSIS → VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →The material filings, RNS and EU notices in one email every market day, read and scored by AI.
Subscribe free →Nov 12 (225) · Nov 10 (146) · Nov 9 (177) · Nov 6 (83) · Nov 5 (348) · Nov 4 (277) · Nov 3 (185) · Nov 2 (126) · Oct 30 (64) · Oct 29 (248) · Oct 28 (199) · Oct 27 (164) · Oct 26 (70) · Oct 23 (37) · Oct 22 (131) · Oct 21 (108) · Oct 20 (68) · Oct 19 (30) · Oct 16 (14) · Oct 15 (37)